The co-occurence of copy gain of chromosome 7 and copy loss of 1p in a subset of tumor samples suggests an activation of EGFR receptor family together with a downregulation of the PI3K/AKT/mTOR pathway, raising the question of a potential sensibility of this subgroup to EGFR inhibitors or to therapies that target more specifically the RAS/MAPK signaling pathway. Here, AKT1 is linked to neoplasm.